SOPHiA GENETICS (SOPH) director details shares, RSUs and options

Rhea-AI Filing Summary

SOPHiA GENETICS SA director Jean-Michel Cossery filed an initial ownership report showing his equity stake in the company. He directly holds 186,488 ordinary shares, including 33,784 shares to be delivered from a restricted share unit award that vests at the next annual shareholder meeting, subject to continued service.

He also holds share options over 59,880 ordinary shares at an exercise price of 2.5300, expiring on October 2, 2033, which vest in thirds annually on the date of the company’s annual shareholder meeting. A further option covers 49,751 ordinary shares at an exercise price of 3.0400, expiring on June 18, 2035, vesting 100% at the next scheduled annual shareholder meeting, also subject to continued service.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Cossery Jean-Michel

(Last) (First) (Middle)

C/O SOPHIA GENETICS SA

LA PIECE 12

(Street)

ROLLE 1180

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	186,488(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	(2)	10/02/2033	Ordinary Shares	59,880	$2.53	D
Share Option (Right to Buy)	(3)	06/18/2035	Ordinary Shares	49,751	$3.04	D

Explanation of Responses:

1. Includes 33,784 ordinary shares to be delivered in settlement of a restricted share unit award ("RSU"). Each RSU represents a contingent right to receive one ordinary share of the Issuer, vesting subject to the Reporting Person's continued service with the Issuer. The RSUs were granted on June 18, 2025 and vest 100% as of the date of the Issuer's next scheduled annual meeting of shareholders.

2. The share options vest over three (3) years from October 2, 2023, with one-third (1/3) vesting annually on the date of the Issuer's annual meeting of shareholders, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.

3. The share options were granted on June 18, 2025 and vest 100% as of the date of the Issuer's next scheduled annual meeting of shareholders, subject to the Reporting Person's continued service to the Issuer through the relevant vesting date.

Remarks:

Exhibit list - Exhibit 24 - Power of Attorney

	/s/ Elimara Brunetto as Attorney-in-fact for Jean-Michel Cossery	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the SOPH Form 3 filing by Jean-Michel Cossery report?

The Form 3 reports Jean-Michel Cossery’s initial ownership in SOPHiA GENETICS SA. It lists his direct holdings of ordinary shares, related restricted share units, and share options, establishing his starting equity position as a director of the company.

How many SOPHiA GENETICS (SOPH) ordinary shares does Jean-Michel Cossery hold?

Jean-Michel Cossery holds 186,488 ordinary shares of SOPHiA GENETICS SA. This figure includes 33,784 ordinary shares to be delivered upon settlement of a restricted share unit award, which vests in full at the next annual shareholder meeting, subject to continued service.

What restricted share units are disclosed in the SOPH Form 3 for Jean-Michel Cossery?

The filing states that 33,784 ordinary shares will be delivered upon settlement of a restricted share unit award. Each RSU represents one ordinary share and vests 100% at the issuer’s next scheduled annual shareholder meeting, contingent on Cossery’s continued service.

What share options does Jean-Michel Cossery hold in SOPHiA GENETICS (SOPH)?

He holds two share option grants over ordinary shares. One covers 59,880 shares at an exercise price of 2.5300, vesting in thirds annually. The other covers 49,751 shares at an exercise price of 3.0400, vesting 100% at the next annual shareholder meeting.

When do Jean-Michel Cossery’s SOPHiA GENETICS share options expire?

One share option grant expires on October 2, 2033, and another expires on June 18, 2035. Both options relate to ordinary shares of SOPHiA GENETICS SA and remain subject to their respective vesting schedules and continued service conditions.

How do the share options for SOPH vest for director Jean-Michel Cossery?

One option grant vests over three years from October 2, 2023, with one-third vesting annually on each annual shareholder meeting date. The other option vests 100% at the issuer’s next scheduled annual shareholder meeting, provided he continues serving through that date.